These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 37572928

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
    Liang J, Qi Z, Liu W, Wang P, Shi W, Dong W, Ji X, Luo Y, Liu KJ.
    Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differences in Acute Expression of Matrix Metalloproteinases-9, 3, and 2 Related to the Duration of Brain Ischemia and Tissue Plasminogen Activator Treatment in Experimental Stroke.
    Wang D, Saleem S, Sullivan RD, Zhao T, Reed GL.
    Int J Mol Sci; 2024 Aug 30; 25(17):. PubMed ID: 39273389
    [Abstract] [Full Text] [Related]

  • 6. Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
    Liu DL, Hong Z, Li JY, Yang YX, Chen C, Du JR.
    J Neuroinflammation; 2021 Jun 24; 18(1):143. PubMed ID: 34162400
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W, Hendren J, Qin XJ, Liu KJ.
    Stroke; 2009 Jul 24; 40(7):2526-31. PubMed ID: 19478225
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
    Shimada Y, Shimura H, Tanaka R, Yamashiro K, Koike M, Uchiyama Y, Urabe T, Hattori N.
    PLoS One; 2018 Jul 24; 13(5):e0198039. PubMed ID: 29795667
    [Abstract] [Full Text] [Related]

  • 13. Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion.
    Yang DY, Pan HC, Chen CJ, Cheng FC, Wang YC.
    Neurol Res; 2007 Apr 24; 29(3):274-82. PubMed ID: 17509227
    [Abstract] [Full Text] [Related]

  • 14. Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
    Liu H, Wang Y, Xiao Y, Hua Z, Cheng J, Jia J.
    Transl Stroke Res; 2016 Jun 24; 7(3):209-19. PubMed ID: 27018013
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
    Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, Huang PL, Wang X, Montaner J, Lo EH.
    Stroke; 2005 Sep 24; 36(9):1954-9. PubMed ID: 16051896
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.
    Ning R, Chopp M, Yan T, Zacharek A, Zhang C, Roberts C, Cui X, Lu M, Chen J.
    Neuroscience; 2012 Oct 11; 222():326-32. PubMed ID: 22820263
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.